Telegraph Hill Partners
300 Montgomery St.San Francisco, CA 94104
Website: thpartners.net
Firm Size
- Assets Under Management (AUM):$1.3 Billion
- Number of Funds:9
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Healthcare
Description
Telegraph Hill Partners is a private equity firm based in San Francisco, California. They specialize in growth-stage investments in the healthcare and life sciences sectors. With over $2 billion in capital under management, they aim to support companies that can drive positive change in the industry and improve patient outcomes. The firm provides strategic guidance, operational support, and financial resources to their portfolio companies to help them achieve their goals. They focus on investing in companies that have unique technologies, innovative products, and promising market potential. Telegraph Hill Partners has a team of experienced professionals with backgrounds in finance, healthcare, and life sciences. They leverage their expertise and network to identify and evaluate investment opportunities. Their investment approach involves creating partnerships with management teams and industry experts to drive growth and value creation. The firm has a strong track record of successful investments in companies that have gone on to become leaders in their respective markets. They have supported a wide range of healthcare and life sciences businesses, including medical devices, diagnostics, pharmaceuticals, healthcare IT, and research tools. Overall, Telegraph Hill Partners is a renowned private equity firm in San Francisco that focuses on investing in growth-stage healthcare and life sciences companies. Through their strategic guidance and financial support, they aim to help these companies bring innovative products and technologies to market, ultimately improving healthcare outcomes for patients.Latest News
Powered by
Mar 27, 2024: EditCo Bio and Telegraph Hill Partners Acquire Synthego's Engineered Cell Solutions Business to Enable Cellular Research
EditCo Bio, Inc. announced that it has launched its business with the acquisition of Synthego's engineered cell solutions and enhanced guide RNA business. Borne from Synthego's cell engineering expertise, EditCo is uniquely positioned to deliver edited cells and highly optimized guide RNA designs for the rapidly expanding CRISPR market. EditCo will operate as an independent business with financing and support from life sciences investment firm Telegraph Hill Partners.